A Study on Swimming Robot

Liu, Xinxiong; Yawei, Liu

doi:10.1109/scet.2012.6342066

Cited by 3 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neonatal sepsis is a major cause of morbidity and mortality. Neonatal sepsis is the third leading cause of neonatal mortality globally, constituting 13% of overall neonatal mortality, only surpassed by intrapartum-related complications (23%) and preterm birth complications (35%) (Lawn 2005;Liu 2012). In highincome countries, the mortality rate in neonatal sepsis ranges from 5% to 20% and results in major disability or death in 39% of all cases despite initiation of conventional treatment.…”

Section: Epidemiologymentioning

confidence: 99%

Antibiotic regimens for early-onset neonatal sepsis

Korang

Safi

Nava

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Section: Epidemiologymentioning

confidence: 99%

Antibiotic regimens for early-onset neonatal sepsis

Korang

Safi

Nava

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…The phase 2 and phase 3 studies by O'Shaughnessy and colleagues (O'Shaughnessy 2011; O'Shaughnessy 2014) investigated benefit for iniparib in patients with metastatic triple-negative breast cancer by comparing iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin alone. These studies were excluded as it was later discovered that iniparib is not a PARP inhibitor (Liu 2012).…”

Section: Excluded Studiesmentioning

confidence: 99%

“…This meta-analysis did not include the studies we have included for our meta-analysis. In fact, the only studies that were included looking at PARP inhibitors in breast cancer specifically were two studies using iniparib (O'Shaughnessy 2011; O'Shaughnessy 2014), which has since been disproved to be a PARP inhibitor mechanistically (Liu 2012).…”

Section: Agreements and Disagreements With Other Studies Or Reviewsmentioning

confidence: 99%

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer

Taylor

Chan

Tio

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Anticipated absolute effects * (95% CI) Outcomes Risk with non-PARPi regimen Risk with PARPi-containing regimen Relative effect (95% CI) № of participants (studies) Certainty of the evidence (GRADE) Comments Study population Overall Survival** follow up: 24 months 550 per 1,000 497 per 1,000 (446 to 550) HR 0.84 (0.76 to 1.00) 1435 (4 RCTs) ⊕⊕⊕⊕ HIGH 1 2 3 4 Study population Progression Free Survival** follow up: 12 months 625 per 1,000 461 per 1,000 (423 to 502) HR 0.63 (0.56 to 0.71) 1474 (5 RCTs) ⊕⊕⊕⊕ HIGH 1 3 5 6 Study population Response Rate 489 per 1,000 695 per 1,000 (636 to 749) RR 1.39 (1.24 to 1.54) 1185 (5 RCTs) ⊕⊕⊝⊝ LOW 1 3 6 7 Study population Grade ≥3 AEs 645 per 1,000 620 per 1,000 (555 to 684) RR 0.98 (0.91 to 1.04) 1443 (5 RCTs) ⊕⊕⊕⊝ MODERATE 1 3 8 9*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).** Given i) overall survival and progression-free survival are continuous endpoints in clinical practice but ii) that continuous measures are not easily quantifiable (even if the HR is available), we opted to estimate the percentage of patients with this outcome (e.g. death) at a predefined time interval to practically estimate the size of treatment benefit for readers. We extrapolated this information from Kaplan-Meier curves from the included studies. We started with the OS at 2 years, then subtracted this from 1 to arrive at incidence of death at 2 years and similarly for PFS at 1 year (BROCADE 2; BROCADE 3; EMBRACA; Kummar 2016; OLYMPIAD). Cochrane LibraryTrusted evidence. Informed decisions. Better health.

show abstract

“…She talked to her former teachers but did not find the time to write things down before she went into retirement. 9 Feng Jinglan 冯敬兰, one of the organizers of the aforementioned symposium, claims that she had begun to work on this issue in 1996, and in 2000 wrote down her recollections of the incident. 10 Ye Weili 叶维丽 reports that she began her research into the death of Bian Zhongyun in 2000/2001.…”

Section: What Happened On 5 August 1966?mentioning

confidence: 99%

Whodunnit? Memory and Politics before the 50th Anniversary of the Cultural Revolution

Weigelin-Schwiedrzik

Jinke

2016

The China Quarterly

View full text Add to dashboard Cite

Song Binbin, the daughter of prominent CCP politician Song Renqiong, has long been accused of having played a role in the death of Bian Zhongyun which took place at the Girls' Middle School in Beijing Normal University on 5 August 1966. In January 2014, she publicly apologized for the violence that occurred at her school during the summer of 1966. However, instead of applauding her act of contrition, rebel participants of the Cultural Revolution used the opportunity to criticize the sons and daughters of high-ranking cadres and to try to overturn the 1981 official evaluation of the Cultural Revolution by promoting a positive view of that period in Chinese history. This paper analyses the background, consequences and implications of Song Binbin's apology from a political science cum memory studies perspective. It argues, against the background of a changing political landscape in the People's Republic of China, that the memory of the Cultural Revolution remains a battlefield of divergent memory groups and multiple narratives. In the memory of today, the struggles of the Cultural Revolution have still not come to an end.

show abstract

A Study on Swimming Robot

Cited by 3 publications

References 14 publications

Antibiotic regimens for early-onset neonatal sepsis

Antibiotic regimens for early-onset neonatal sepsis

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer

Whodunnit? Memory and Politics before the 50th Anniversary of the Cultural Revolution

Contact Info

Product

Resources

About